9 news items
Genmab Completes Acquisition of ProfoundBio
GMAB
21 May 24
and continue to work towards our goal of transforming the lives of patients with innovative antibody medicines
Genmab Completes Acquisition of ProfoundBio
GMAB
21 May 24
of transforming the lives of patients with innovative antibody medicines." The acquisition gives Genmab worldwide rights to ProfoundBio's
Genmab to Present New and Updated Results From Multiple Clinical Trials Evaluating Epcoritamab Across Various B-Cell Malignancies at the 2024 European Hematology Association (EHA) Congress
GMAB
14 May 24
improving the lives of patients through innovative and differentiated antibody therapeutics. For 25 years, its passionate, innovative
FDA Grants Full Approval for TIVDAK® to Treat Recurrent or Metastatic Cervical Cancer
GMAB
PFE
29 Apr 24
unstoppable team to strive towards improving the lives of patients through innovative and differentiated antibody therapeutics. For 25 years, its passionate
TIVDAK® (tisotumab vedotin-tftv) Receives U.S. FDA Approval to Treat Recurrent or Metastatic Cervical Cancer
GMAB
PFE
29 Apr 24
unstoppable team to strive towards improving the lives of patients through innovative and differentiated antibody therapeutics. For 25 years, its
29fjfr otygs1uenabp
GMAB
PFE
29 Apr 24
towards improving the lives of patients through innovative and differentiated antibody therapeutics. For 25 years, its passionate, innovative
xzxwarcbvew19zlaeukl6
AVBP
GMAB
LLY
8 Apr 24
for $1.8 billion
The deal is the fourth acquisition of a China-related innovative drugmaker by a foreign company in the last four months
oei2cijrj
GMAB
3 Apr 24
2030 vision, to impact the lives of patients through innovative antibody medicines," said Jan van de Winkel, Ph.D., President and Chief Executive
ogr2vveb348sxw9j9a2qqk1 gv7wukrzbr
ABBV
GMAB
27 Feb 24
innovative and differentiated antibody therapeutics. For more than 20 years, its passionate, innovative and collaborative team has invented next
- Prev
- 1
- Next